Sangamo Biosciences (NASDAQ: SGMO) reported Q4 EPS of ($0.06), $0.03 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $14.95 million versus the consensus estimate of $14.5 million.

Sangamo Biosciences sees FY2015 revenue of $60-70 million, versus the consensus of $65.35 million.

Sangamo expects that its cash, cash equivalents and marketable securities will be at least $180 million at the end of 2015, inclusive of research funding and certain milestone payments from Shire and Biogen but exclusive of funds arising from any additional new collaborations or partnerships, equity financings or other new sources.

Sangamo expects that operating expenses will be in the range of $100 million to $110 million for 2015.

For earnings history and earnings-related data on Sangamo Biosciences (SGMO) click here.